'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study.
D MitreaN BarbetT Pacé-LoscosC ScouarnecS Ben-DhiaD BaronL MineurL ÉvesqueJ Durand-LabrunieJ-P GérardG BaudinJ DoyenPublished in: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2024)
The preliminary results of this feasibility study show that early tolerance of these intensive total neoadjuvant treatment is compatible with an acceptable toxicity. The high rate of organ preservation in this intermediate group of T2-T3 tumours is encouraging and is a good argument to start the next randomized TRESOR trial that will aim at achieving a 65% of 3-year survival with organ preservation in this intermediate tumour group.
Keyphrases
- locally advanced
- rectal cancer
- dual energy
- squamous cell carcinoma
- phase iii
- radiation therapy
- image quality
- computed tomography
- phase ii
- open label
- clinical trial
- double blind
- study protocol
- high dose
- high resolution
- minimally invasive
- randomized controlled trial
- mass spectrometry
- positron emission tomography
- combination therapy
- replacement therapy
- pet ct